The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis
Open accessAbstract
Vaccines that drive robust T-cell immunity against Mycobacterium tuberculosis (Mtb) are needed both for prophylactic and therapeutic purposes. We have recently developed a synthetic vaccine delivery platform with Pluronic-stabilized polypropylene sulfide nanoparticles (NPs), which target lymphoid tissues by their small size (∼ 30 nm) and which activate the complement cascade by their surface chemistry. Here we conjugated the tuberculosis antigen Ag85B to the NPs (NP-Ag85B) and compared their efficacy in eliciting relevant immune responses in mice after intradermal or pulmonary administration. Pulmonary administration of NP-Ag85B with the adjuvant CpG led to enhanced induction of antigen-specific polyfunctional Th1 responses in the spleen, the lung and lung-draining lymph nodes as compared to soluble Ag85B with CpG and to the intradermally-delivered formulations. Mucosal and systemic Th17 responses were also observed with this adjuvanted NP formulation and vaccination route, especially in the lung. We then evaluated protection induced by the adjuvanted NP formulation following a Mtb aerosol challenge and found that vaccination with NP-Ag85B and CpG via the pulmonary route displayed a substantial reduction of the lung bacterial burden, both compared to soluble Ag85B with CpG and to the corresponding intradermally delivered formulations. These findings highlight the potential of administrating NP-based formulations by the pulmonary route for TB vaccination.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pulmonary administration of the common TB antigen 85B conjugated to poly(propylene sulphide) nanoparticles demonstrated improved protection in mice after they were challenged with aerosolized M. tuberculosis (ref. 135 ).”
From Nanotechnology approaches for global infectious diseases (2021) · cites this paper as [135]
Citations
Cites
Lutz, M. B., Kukutsch, N. A., Ogilvie, A. L. J., Rößner, S., Koch, F., Romani, N., & Schuler, G. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00204-x · Cited by 2,972
Sample criteria for testing outlying observations
Grubbs, F. E. (1950) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177729885 · Cited by 1,631
Khader, S. A., Bell, G. K., Pearl, J. E., Fountain, J. J., Rangel‐Moreno, J., Cilley, G. E., Shen, F., Eaton, S. M., Gaffen, S. L., Swain, S. L., et al. (2007) · Nature Immunology · doi:10.1038/ni1449 · Cited by 1,468
Exploiting lymphatic transport and complement activation in nanoparticle vaccines
Reddy, S. T., van der Vlies, A. J., Simeoni, E., Angeli, V., Randolph, G. J., O’Neil, C. P., Lee, L. K., Swartz, M. A., & Hubbell, J. A. (2007) · Nature Biotechnology · doi:10.1038/nbt1332 · Cited by 1,355
Self-citationGlobal tuberculosis control 2010
Behera, D. (2012) · The Indian Journal of Medical Research · Cited by 1,262
Induction and effector functions of TH17 cells
Bettelli, E., Korn, T., Oukka, M., & Kuchroo, V. K. (2008) · Nature · doi:10.1038/nature07036 · Cited by 1,243
The success and failure of BCG — implications for a novel tuberculosis vaccine
Andersen, P. L., & Doherty, T. M. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1211 · Cited by 791
Immune Control of Tuberculosis by IFN-γ-Inducible LRG-47
MacMicking, J. D., Taylor, G. A., & McKinney, J. D. (2003) · Science · doi:10.1126/science.1088063 · Cited by 685
Self-citationMaterials engineering for immunomodulation
Hubbell, J. A., Thomas, S. N., & Swartz, M. A. (2009) · Nature · doi:10.1038/nature08604 · Cited by 581
Self-citationUptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome
Sharp, F. A., Ruane, D., Claass, B., Creagh, E. M., Harris, J., Malyala, P., Singh, M., O’Hagan, D. T., Pétrilli, V., Tschopp, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804897106 · Cited by 536
Cited by
Sorted by citations
Items 101–129 of 129
Renauld, A., & Sverdlik, R. C. (1975) · PubMed · Cited by 3
Yun, J.-S., Kim, S.-M., Lee, J. S., Jeong, S. H., Oh, H., Son, P., Kim, S., Lee, Y.-R., Shin, E., Ha, S., et al. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02105-2 · Cited by 2
Hsu, W.-L., Jiao, Y., Hvasta, M. G., Tran, K. N., Troyer, B. T., Huang, W., Kuhlman, B. A., Obregón‐Henao, A., & Lovell, J. F. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128281 · Cited by 2
Abebe, F. (2014) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000254 · Cited by 4
Biomaterials for Engineering Immune Responses
Jhunjhunwala, S. (2018) · Journal of the Indian Institute of Science · doi:10.1007/s41745-018-0063-7 · Cited by 2
DRY POWDER INHALATION OF PNEUMOCOCCAL VACCINE USING POLYMERIC NANOPARTICLES AS CARRIERS
Kunda, N. (2016) · Liverpool John Moores University · doi:10.24377/ljmu.t.00004462 · Cited by 2
Ou, B. S., Baillet, J., Picece, V. C. T. M., Gale, E. C., Powell, A. E., Saouaf, O. M., Yan, J., Nejatfard, A., Hernandez, H. L., & Appel, E. A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.02.522505 · Cited by 2
Morgun, E., Zhu, J. Y., Almunif, S., Bobbala, S. K. R., Aguilar, M. S., Wang, J., Conner, K., Cui, Y., Cao, L., Seshadri, C., et al. (2023) · eLife · doi:10.7554/elife.87431.1 · Cited by 2
Puvvada, N., Chandu, B., & Panigrahi, P. K. (2025) · Wiley eBooks · doi:10.1002/9781394200559.ch11 · Cited by 2
Nanotechnology-based approaches against COVID-19
Abolmaali, S. S., Alimardani, V., Farahavar, G., Najafi, H., Shafiee, M., Tanideh, N., Tamaddon, A. M., & Ahadian, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90792-7.00012-9 · Cited by 1
Fourth International Conference: Modern Vaccines/Adjuvants Formulation—Impact On Future Development
Tupin, E. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.25934 · Cited by 1
Morgun, E., Zhu, J. Y., Almunif, S., Bobbala, S. K. R., Aguilar, M. S., Wang, J., Conner, K., Cui, Y., Cao, L., Seshadri, C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.07.531489 · Cited by 1
Afrose, A. (2017) · Queensland University of Technology · doi:10.5204/thesis.eprints.107550
Probing and Overcoming Extracellular Barriers to Inhaled Nanomedicine
Schuster, B. S. (2014)
Imunização pulmonar com nanopartículas contendo o antígeno PspA (Pneumococcal surface protein A)
Rodrigues, T. C. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.87.2019.tde-05042019-135722
Reassessing Twenty Years of Vaccine Development Against Tuberculosis
Schaible, U. E., & Kaufmann, S. H. E. (2018) · Frontiers research topics · doi:10.3389/978-2-88945-446-4 · Cited by 2
Development of a Mucosal TB Vaccine Using Human Parainfluenza Type 2 Virus
Tsujimura, Y., & Yasutomi, Y. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-811924-2.00035-3
AN OVERVIEW OF SUBUNIT-BASED VACCINES FOR PULMONARY ADMINISTRATION
Ongun, M., MUTLU-AĞARDAN, B., & Acartürk, F. (2021) · Ankara Universitesi Eczacilik Fakultesi Dergisi · doi:10.33483/jfpau.800507
Clinical perspectives of nanotherapy in tuberculosis treatment
Sharma, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819985-5.00002-4
In vivo imaging of T cells loaded with gold nanoparticles: a pilot study
Cheng, X. L. (2014)
Galliverti, G., Tichet, M., Domingos‐Pereira, S., Hauert, S., Nardelli‐Haefliger, D., Swartz, M. A., Hanahan, D., & Wullschleger, S. (2023) · doi:10.1158/2326-6066.c.6548929
Self-citationCOVID-19: Molecular Pathogenesis and Prospective Therapeutic Interventions
Shrivastava, P., & Vyas, S. P. (2023) · Springer eBooks · doi:10.1007/978-3-031-20537-8_12
Morgun, E., Zhu, J. Y., Almunif, S., Bobbala, S. K. R., Aguilar, M. S., Wang, J., Conner, K., Cui, Y., Cao, L., Seshadri, C., et al. (2023) · eLife · doi:10.7554/elife.87431.2
Vaccine delivery systems for immunization
Askari, V. R., Yahyazadeh, R., & Rahimi, V. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-91816-9.00005-9
Nanomaterial’s role against SARS-CoV-2 pandemic and beyond
Singh, R., Saji, J., Saini, A., Umapathi, A., Kumawat, M., Mathur, P., & Daima, H. K. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/bk9781837674138-00177
Diagnosis and Treatment of COVID-19 Using Nanomedicinal Approach
Sharma, K., Sakshi, Vaishali, Vikal, S., Gautam, D., Gautam, Y. K., & Singh, B. P. (2024) · Springer eBooks · doi:10.1007/978-981-97-7445-6_47
Theoretical Approach: Noble Metal Nanoparticles for Combating the Omicron Variant of SARS-CoV-2
Elsheshiny, A. A. A., Abdelfattah, S. S., & Elfeky, A. (2026) · GAZI UNIVERSITY JOURNAL OF SCIENCE · doi:10.35378/gujs.1602764
Files, M. A., Das, A., Kim, D., Buck, J., Endsley, J. J., & Rudra, J. S. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04305-5
Metadata
- Authors
- Ballester, M., Nembrini, C., Dhar, N., de Titta, A., de Piano, C., Pasquier, M., Simeoni, E., van der Vlies, A. J., McKinney, J. D., Hubbell, J. A., & Swartz, M. A.
- Affiliations
- École Polytechnique Fédérale de Lausanne (CH)
- Corresponding author
- Hubbell, Jeffrey A.
- Swartz, Melody A.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2011-09
- Volume
- 29
- Issue
- 40
- Pages
- 6959-6966
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W1967877494
- Cited by
- 130
- References
- 33
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 8 · 2023: 12 · 2022: 1 · 2021: 9 · 2020: 6 · 2019: 8 · 2018: 13 · 2017: 9 · 2016: 7 · 2015: 7 · 2014: 15 · 2013: 16 · 2012: 10
- FWCI
- 8.85
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Licence
- Locations
- Vaccine (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Funders
- Bill and Melinda Gates Foundation
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- tuberculosis vaccination, Ag85B, CpG adjuvant, nanoparticle conjugation, Th1 response, Th17 response, Mycobacterium tuberculosis, aerosol challenge, lung bacterial burden, complement activation
- MeSH terms
- Acyltransferases, Animals, Antigens, Bacterial, Bacterial Proteins, Complement System Proteins, Dendritic Cells, Lung, Lymph Nodes, Mice, Inbred C57BL, Mycobacterium tuberculosis, Particle Size, Polypropylenes, Spleen, Tuberculosis, Vaccines, Synthetic, Th1 Cells, Immunoconjugates, CpG Islands, Tuberculosis Vaccines, Mice, Nanoparticles, Th17 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
